Investor Presentaiton

For personal use only ProstACT program overview Multiple opportunities to deliver insights into TLX591 TELIX PHARMACEUTICALS Radiogenomics study • ~50 patients 1st line metastatic prostate cancer (mCRPC) Rapid recruitment Combination with EBRT in oligometastatic early recurrence (Phase II) • ~50 patients Co-funded by GenesisCare PROSTACT SELECT Treat the scan Correlation between imaging and therapy to optimise patient selection & PROSTACT TARGET - SELECT (Ph I) – radiogenomics study enhances patient selection and supports indication expansion based on a "theranostic" approach Pivotal Phase III study in patients with mCRPC progressing on 1st line novel androgen agents ⚫ 390 patients • 2nd line mCRPC Early data in front line care Efficacy data in patients in their first recurrence PROSTACT GLOBAL TLX591 + Standard of Care (SoC) vs. SoC alone TARGET (Ph II) – in partnership with GenesisCare, evaluates TLX591 in a front-line setting GLOBAL (Ph III) - Multiple data read-outs throughout the ProstACT program duration Telix Pharmaceuticals Limited (ASX: TLX) 29 29

View entire presentation